SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
Abstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-...
Main Authors: | Abdulaziz Almuqrin, Andrew D. Davidson, Maia Kavanagh Williamson, Philip A. Lewis, Kate J. Heesom, Susan Morris, Sarah C. Gilbert, David A. Matthews |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Genome Medicine |
Online Access: | https://doi.org/10.1186/s13073-021-00859-1 |
Similar Items
-
Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species
by: Sultan Nafea Alharbi, et al.
Published: (2021-03-01) -
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
by: Teresa Lambe, et al.
Published: (2021-07-01) -
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
by: Glenn A. Marsh, et al.
Published: (2021-05-01) -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Sue Ann Costa Clemens, et al.
Published: (2021-10-01) -
Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01)